FDA Approves Injectable Opdivo for Many Types of Cancer
5 days ago · “This approval of subcutaneous nivolumab gives our patients a new option that can deliver consistent efficacy and comparable safety expected from IV nivolumab and offers a patient-centric treatment experience,” Saby George, MD, of Roswell Park Comprehensive Cancer Center, said in a news release. “Opdivo Qvantig offers faster ...
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
1 day ago · Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue.
Halozyme Announces FDA Approval of Bristol Myers Squibb's …
Dec 30, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and ...
FDA Approves Subcutaneous Immunotherapy Opdivo Qvantig
1 day ago · News. The FDA has approved a new way to receive a cancer treatment called nivolumab (Opdivo). This new version, called Opdivo Qvantig, can be given as an injection under the skin instead of through an IV. ... George S, Bourion MT, Chacon MR, et al. Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously ...
FDA Approves Nivolumab and Hyaluronidase-nvhy for …
6 days ago · On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab combination therapy, or in combination with chemotherapy or …
Last Month in Oncology: FDA Cancer News Roundup - Medscape
1 day ago · 1. The FDA approved a subcutaneous formulation for nivolumab and hyaluronidase (Opdivo Qvantig, Bristol Myers Squibb Company) for most previously approved solid tumor nivolumab indications in ...
FDA Approves First Subcutaneous Nivolumab Injection in Most …
5 days ago · Additionally, a key powered secondary end point showed an overall response rate (ORR) of 24% (95% CI, 19-30) in the nivolumab and hyaluronidase-nvhy arm, compared with 18% (95% CI, 14-24) in the ...
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase …
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human hyaluronidase ...
Nivolumab and AVD the New Standard in Hodgkin Lymphoma
Nov 14, 2024 · In the nearly 1,000-patient trial, treatment with nivolumab and a three-drug chemotherapy regimen called AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD combined with the targeted therapy brentuximab (Adcetris).
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid …
5 days ago · FRIDAY, Jan. 3, 2025 -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications. Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant human hyaluronidase.
- Some results have been removed